» Articles » PMID: 33388322

HPV Vaccination Introduction Worldwide and WHO and UNICEF Estimates of National HPV Immunization Coverage 2010-2019

Abstract

WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently approved global strategy for cervical cancer elimination as a public health problem. As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 (6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated at 15%. There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, specially ensuring the most populous countries introduce, and further improving program performance globally.

Citing Articles

Human papillomavirus and prostate cancer in Mexican men: a systematic review and meta-analysis.

Arriaga-Izabal D, Morales-Lazcano F, Canizalez-Roman A Cancer Causes Control. 2025; .

PMID: 40088360 DOI: 10.1007/s10552-025-01989-2.


Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.

Gao M, Hu S, Zhao X, You T, Hong Y, Liu Y Lancet Reg Health West Pac. 2025; 56:101499.

PMID: 40061912 PMC: 11889945. DOI: 10.1016/j.lanwpc.2025.101499.


Gender-neutral vs. gender-specific strategies in school-based HPV vaccination programs: a systematic review and meta-analysis.

Chandeying N, Khantee P, Puetpaiboon S, Thongseiratch T Front Public Health. 2025; 13:1460511.

PMID: 40041177 PMC: 11876415. DOI: 10.3389/fpubh.2025.1460511.


HPV vaccination among young adults in Switzerland: a cross-sectional study.

El-Hadad S, Sachs M, Barrense-Dias Y, Granell J, Niggli A, Leeners B BMJ Open. 2025; 15(2):e089681.

PMID: 39938962 PMC: 11831261. DOI: 10.1136/bmjopen-2024-089681.


Effectiveness of the Traditional Japanese Herbal Medicine, Yokuinin (Kampo), in the Treatment of Cervical Precancerous Lesions.

Kiyoshima C, Kimura I, Ishida K, Hirano T, Ishida T, Shigekawa K Cureus. 2025; 17(1):e77114.

PMID: 39925535 PMC: 11802933. DOI: 10.7759/cureus.77114.